Literature DB >> 1747020

Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia.

W S Fenton1, T H McGlashan.   

Abstract

To explore the validity of different approaches for subtyping schizophrenia, the conditions of 187 schizophrenic patients from the Chestnut Lodge follow-up study were rediagnosed with the use of classic subtype criteria. Independently collected data allowed construction of a longitudinal profile of the natural history of illness for patients who met operational criteria for paranoid (n = 78), hebephrenic (n = 26), and undifferentiated (n = 83) schizophrenia. Paranoid schizophrenia had an older age at onset, often developed rapidly in individuals with good premorbid functioning, tended to be intermittent during the first 5 years of illness, and was most associated with good outcome or recovery. Hebephrenia had an earlier age at onset, often developed insidiously, and was associated with a greater family history of psychopathology, poor premorbid functioning, and, frequently, a continuous illness with a poor long-term prognosis. While also early and insidious in onset, unlike hebephrenia, undifferentiated schizophrenia was poorly distinguished from the patients' premorbid state, associated with an early history of behavioral difficulties, and often resulted in a continuous but stable disability. We discuss implications for nosology. Although distinctive patterns were discernible, the considerable heterogeneity within subtypes calls for continued efforts to develop and explore alternate classification schemes.

Entities:  

Mesh:

Year:  1991        PMID: 1747020     DOI: 10.1001/archpsyc.1991.01810350009002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  21 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.

Authors:  Thomas H McGlashan; William T Carpenter
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

3.  Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11.

Authors:  J W Keeley; W Gaebel
Journal:  Epidemiol Psychiatr Sci       Date:  2017-06-19       Impact factor: 6.892

4.  A 16-year follow-up of patients with serious mental illness and co-occurring substance use disorder.

Authors:  Robert E Drake; Haiyi Xie; Gregory J McHugo
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

5.  Subtyping Schizophrenia by Social Functioning - a Pragmatic Proposal for Clinics and Research.

Authors:  Takefumi Suzuki
Journal:  Psychiatr Q       Date:  2018-09

Review 6.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

7.  Abnormal auditory sensory gating-out in first-episode and never-medicated paranoid schizophrenia patients: an fMRI study.

Authors:  Bin Ji; Wei Mei; John X Zhang; Juzhen Jing; Qiulin Wu; Yongning Zhuo; Zhuangwei Xiao
Journal:  Exp Brain Res       Date:  2013-07-03       Impact factor: 1.972

8.  Subtypes in schizophrenic disorders: frequencies in long-term course and premorbid features.

Authors:  A Deister; A Marneros
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1993-08       Impact factor: 4.328

9.  Long-term stability of subtypes in schizophrenic disorders: a comparison of four diagnostic systems.

Authors:  A Deister; A Marneros
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

Review 10.  Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells.

Authors:  Bradley Watmuff; Shaunna S Berkovitch; Joanne H Huang; Jonathan Iaconelli; Steven Toffel; Rakesh Karmacharya
Journal:  Mol Cell Neurosci       Date:  2016-01-14       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.